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than agonist. Pre-clinical laboratory data suggest a number 
of mechanisms whereby GnRH antagonist therapy may ben-
efit men with pre-existing cardiovascular disease (CVD), the 
most plausible hypothesis being that, unlike GnRH agonists, 
GnRH antagonists do not activate T lymphocytes, which act 
to increase atherosclerotic plaque rupture.
Conclusion When making treatment decisions, clinicians 
should consider comorbidities, particularly CVD, in addition 
to effects on PC. GnRH antagonists may be appropriate in 
patients with significant CV risk, existing osteopenia, lower 
urinary tract symptoms and significant metastatic disease.
Keywords ADT · GnRH · Prostate cancer · Degarelix · 
UK · Cardiovascular
Introduction
Prostate cancer (PC) is the second most common cancer 
in men worldwide, with approximately 1.09 million men 
diagnosed in 2012, accounting for 15 % of all cancers in 
men [1]. In the UK, it is the most common cancer in men, 
with approximately 45,400 diagnoses and 10,600 deaths 
attributed to PC in 2012 [1]. Additionally, men with PC 
represent a high-risk population for cardiovascular disease, 
with many of the risk factors for PC being associated with 
high risk of CVD (e.g. obesity, diet, sedentary lifestyle). 
The commonest non-PC cause of death in such men is 
CVD.
Since the 1940s, the first-line treatment for advanced 
PC has been ADT, after it was demonstrated that surgical 
castration resulted in significant clinical improvement [2]. 
The irreversibility of the surgical procedure, along with its 
understandable lack of popularity with patients and clini-
cians, has led to increased use of chemical castration, with 
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nists and antagonists in the published literature in order 
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ing to ensure that the latest data and opinion were available 
for the discussions.
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there is evidence of improved disease control by a GnRH 
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progression and greater reduction of serum alkaline phos-
phatase. In a post hoc analysis of six randomised trials, the 
risk of cardiac events within 1 year of initiating therapy was 
significantly lower among men receiving GnRH antagonist 
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GnRH agonists being introduced in the 1980s, followed by 
GnRH antagonists in 2003 [3].
Recent epidemiological evidence has linked ADT with 
increased non-PC mortality seemingly due to increased 
CV mortality. Studies comparing orchiectomy with GnRH 
agonists suggest that agonist therapy may have morbid-
ity above that seen with surgical castration. Most recently, 
a meta-analysis of a number of comparative trials between 
GnRH agonists and antagonists has revealed fundamental 
differences in outcomes between the two classes of drug. 
The purpose of the current paper is to provide an up to date 
review of the potential risks and benefits of the options 
available for ADT, so as to guide clinicians and patients as 
to the best likely option in any given situation.
Rationale for use of ADT
The overall aim of ADT in advanced PC is to reduce testos-
terone levels, thereby minimising an important stimulus to 
androgen-sensitive PC cells and causing them to undergo 
apoptosis [3, 4]. ADT delays disease progression [5] and 
can also result in the dramatic reduction of skeletal metas-
tases, decreased post-void residual urine and improved 
quality of life (QoL) [6].
GnRH agonists
The GnRH agonists currently available share broadly simi-
lar overall survival outcomes [3] and achieve similar clini-
cal improvements, such as reductions in bone pain, spinal 
cord compression risk and ureteral obstruction in the longer 
term [7]. Typically, GnRH agonists are indicated for the 
treatment of locally advanced/metastatic PC, as well as 
neo-adjuvant or adjuvant use with radiotherapy in high-risk 
localised or locally advanced PC [8].
Although GnRH agonists are the current standard of 
care, there are several factors relating to their mechanism 
of action to consider when selecting appropriate patients 
(Fig. 1). GnRH agonists work by overstimulating GnRH 
receptors, resulting in receptor desensitisation over time, 
with a consequent reduction in luteinising hormone (LH) 
and follicle-stimulating hormone (FSH) production, and 
reduced testosterone production [9] (Fig. 1). Testoster-
one suppression is only achieved after an initial LH surge 
that not only delays the testosterone reaching castrate lev-
els, but also stimulates overproduction of testosterone for 
the first 30 days [9]. This potentially results in transient 
tumour expansion and a resultant flare in clinical symp-
toms, including worsened bone pain, urinary obstruction, 
spinal cord compression and potential CV effects [3, 9, 10]. 
Additionally, 5–17 % of men do not achieve acceptable tes-
tosterone suppression of ≤50 ng/dL [11], and 13–34 % do 
not achieve the more widely accepted modern threshold of 
20 ng/dL [12–14].
GnRH antagonists
A major advantage of the GnRH antagonists is their imme-
diate onset of action, with more rapid and sustained sup-
pression of testosterone than the GnRH agonists [15]. This 
is evidenced by rapid reduction in local symptoms [9] and 
Fig. 1  Contrasting modes of action of GnRH agonists and antagonists
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in PSA. Furthermore, antagonists do not elicit the testoster-
one surge associated with agonists [16] obviating the need 
to add anti-androgens to the treatment regimen [15].
When degarelix (the only GnRH antagonist currently 
licensed in the UK) efficacy was compared with leuprore-
lin in a 12-month, randomised, open-label study, rapid tes-
tosterone suppression (testosterone levels ≤0.5 ng/mL by 
3 days) was achieved in 96.1 % of patients, compared with 
none in the leuprolide group [15]. This rapid and predict-
ably sustained testosterone suppression, which avoids the 
negative clinical effects associated with flare, more closely 
resembles the ‘gold standard’ ADT of surgical castration 
[16].
The role of FSH and the need for sustained FSH 
suppression
The rapid testosterone suppression caused by degarelix 
was preceded by a similarly rapid decrease in LH and FSH 
levels that was maintained until the end of the study [15]. 
Furthermore, in the follow-up crossover study, FSH was 
further suppressed in patients switching from leuprolide to 
degarelix, with levels reaching those in patients receiving 
continuous degarelix treatment throughout the initial study 
[17].
FSH suppression is potentially important because of 
FSH’s role in tumour growth, bone resorption and regula-
tion of adipocytes and obesity [18]. FSH-receptor-positive 
blood vessels have been identified in a 10-mm-thick tis-
sue layer that extends into and outside the PC tumour mass 
[19]. Location of these cells in normal tissue immediately 
adjacent to tumour tissue is consistent with the hypothesis 
that tumour cells at the invasive front attract surrounding 
blood vessels to the tumour, with FSH-receptor expression 
being activated and consequently driving the proliferative 
process [19]. There may be additional benefits to suppress-
ing FSH: the presence of FSH receptors in bone tissue has 
been implicated in accelerated bone resorption in post-
menopausal women with raised FSH [20].
PSA monitoring
Since its identification, PSA remains a controversial bio-
marker for PC screening [21]; however, the use of PSA as a 
marker for treatment response, prognosis and monitoring of 
disease progression is widely accepted [22–24]. The rate of 
PSA decline (PSA half-life) may also be of prognostic sig-
nificance [25, 26]: in a study of 153 patients receiving hor-
monal therapy, Lin et al. [25] found that shorter PSA half-
life (≤0.5 months) was associated with significantly longer 
progression-free survival (PFS) and overall survival (OS) 
(median 24.6 and 48 months, respectively) than longer PSA 
half-life (median 17.2 and 43 months, respectively).
In the initial degarelix study and the subsequent crosso-
ver study, improved PSA-PFS associated with degarelix 
was also associated with delayed progression to castration-
resistant PC (CRPC). PSA failure (defined as two con-
secutive PSA increases ≥50 % of nadir and ≥5 ng/mL in 
two consecutive measurements at least 2 weeks apart) [9] 
occurred mainly in patients with advanced disease and 
exclusively in patients with baseline PSA >20 ng/mL [22, 
27]. In patients with baseline PSA >20 ng/mL, PSA recur-
rence was significantly less frequent for those receiving 
degarelix than for those receiving leuprolide (p = 0.04) 
[22]. Time to PSA failure or death in 25 % of these patients 
was also significantly longer for degarelix than for leu-
prolide (514 vs. 303 days; p = 0.01), i.e. progression or 
death was delayed by approximately 7 months longer with 
degarelix than with leuprolide [28].
The stronger correlation of PSA progression with sur-
vival in patients with hormone-sensitive PC receiving ADT, 
compared with patients with CRPC receiving chemother-
apy is partly influenced by the disease’s natural history and 
the efficacy of available therapies in each setting [24]. Clin-
ically, the goal of delaying PSA progression is important: 
PSA progression and subsequent emergence of castrate-
resistant disease may trigger a move to chemotherapy, with 
its potential physical and psychological morbidities [16].
Serum alkaline phosphatase
Bone metastases in PC are usually osteoblastic (i.e. they 
cause bone deposition), but these cancer cells can affect 
bones in two contrasting ways. Osteoclastic activity 
involves bone being broken down without new bone being 
formed, leading to osteolytic or lytic lesions that leave bone 
vulnerable to fracture. Osteoblastic activity involves new 
bone being formed without old bone being broken down 
first. The affected areas of the bones, osteoblastic or blas-
tic lesions, become harder (sclerosis), but at the same time 
more brittle. This bone activity leads to elevated levels of 
parathyroid hormone (PTH), which promotes the growth 
and invasiveness of PC cells in bone. Thus, blastic metas-
tases induce a vicious cycle in which PTH induces resorp-
tion of normal bone to support growth of bone metastases 
elsewhere [29].
In PC, elevated S-ALP levels appear to be predictive of 
progression of bone metastases and early mortality, with 
S-ALP at 6 months after treatment initiation giving bet-
ter prediction of survival than baseline S-ALP [30]. An 
exploratory S-ALP analysis from the degarelix phase 3 
study found that after initial peaks in all treatment groups, 
S-ALP was significantly more suppressed in patients with 
 World J Urol
1 3
metastatic PC by degarelix than by leuprolide (96 vs. 
179 IU/L; p = 0.014) [31]. Thus, degarelix may offer better 
S-ALP control than leuprolide and improve control of skel-
etal metastases over a 1-year period [31].
Initiating ADT for advanced PC
ADT for advanced PC should always be tailored to the 
individual patient. Those experiencing symptoms such as 
spinal/bone pain or lower urinary tract symptoms (LUTS) 
should be assessed as to whether they might benefit from 
the more rapid reduction in testosterone, without associated 
testosterone and potential tumour flare, offered by a GnRH 
antagonist.
The clinical benefits of rapid testosterone reduction 
to castrate levels include reduction in intensity of lumbar 
back pain [32] and resolution of hydronephrosis and other 
LUTS [33]. Although the extension study from the degare-
lix phase 3 study has suggested some improvement in PSA-
PFS [17], there are limited data available to make any firm 
conclusions regarding the benefits of switching between 
ADT modalities. Patients who experience an increase 
in PSA during ADT should have their testosterone levels 
retested before making further treatment decisions. Some 
patients may still be hormone responsive and therefore may 
be able to benefit from a switch to antagonist therapy [17].
Adverse events associated with ADT
Chemical ADT is associated with a number of adverse 
events (AEs), including CVD, cognitive function effects 
[34–36], skeletal events, muscular pain, general pain and 
LUTS [7, 14]. In the CS21 phase 3 study of degarelix ver-
sus leuprolide, both agents were generally well tolerated, 
with a similar incidence of treatment-related AEs (79 and 
78 % of patients in the degarelix and leuprolide groups, 
respectively) [15]. Most reported AEs were of mild-to-
moderate intensity. Of note, degarelix was associated with 
a significantly higher incidence of injection site reactions 
(ISR) than leuprorelin (40 vs. <1 %; p = 0.001), with reac-
tions occurring predominantly after the initiation dose 
[15]. This difference may have been due to the method of 
injection (subcutaneous for degarelix, intramuscular for 
leuprorelin), and the fact that reactions occurred most fre-
quently with the initiation dose may be because a double 
injection is required for treatment initiation; an ISR was 
rarely seen with subsequent injections.
Additionally, chemical ADT is associated with sexual 
dysfunction [37], weight gain [15] and metabolic syn-
drome, and may be associated with raised triglycerides and 
cholesterol, reduced insulin sensitivity and type 2 diabetes 
[38, 39]. Weight gain, elevated triglycerides and type 2 
diabetes are all CV risk factors. ADT has also been associ-
ated with an increased risk of CV events, compared with 
orchidectomy, including arterial embolic or thrombotic 
events, haemorrhagic or ischaemic cerebrovascular condi-
tions, myocardial infarction (MI), heart failure and other 
ischaemic heart diseases [4, 40–44].
Management of patients with increased CV risk
Given the risk factors for development of invasive PC and 
the patient demographics in PC, it is likely that at least 
one-third will have pre-existing vascular disease [40]. Fur-
thermore, CVD is the most common cause of death in men 
with PC who do not die of the disease itself [45].
In 2010, the US Food and Drug Administration (FDA) 
asked manufacturers of GnRH analogues to add extra 
safety information to drug labels concerning the increased 
risk of diabetes and certain CV diseases (heart attack, sud-
den cardiac death, stroke) in men with PC [46], based on 
the epidemiological data [41]. Men with a history of CVD 
are most at risk, with agonists being significantly associ-
ated with increased risk of all-cause morbidity in men with 
a history of CVD-induced congestive heart failure or MI, 
but not in those with no comorbidities or only one CV risk 
factor [42].
In an analysis of pooled data from six phase 3, prospec-
tive, randomised trials of GnRH agonists versus antagonist 
involving more than 2300 men with PC [40], antagonist-
based ADT appears to halve the number of cardiac events 
in men with pre-existing CVD during the first year of 
treatment, compared with agonists. In men with pre-exist-
ing CVD, there was a 56 % lower risk of a cardiac event 
(absolute risk reduction 8.2 %) in the first year of initiating 
ADT with a GnRH antagonist than with a GnRH agonist 
(HR 0.44; 95 % CI 0.26–0.74; p = 0.002; number needed 
to treat = 12) [40]. The magnitude of this risk reduction 
can be put into context by considering treatments intended 
to reduce risk in populations at high risk of CV events. For 
example, the landmark 4S simvastatin study demonstrated 
a 34 % relative risk reduction versus placebo over 5.4 years 
[47].
Potential mechanisms of increased CV risk 
associated with GnRH agonists
GnRH agonists and antagonists both induce castrate lev-
els of testosterone, which is associated with increased CV 
risk [40]. Traditionally, this risk has been attributed to 
metabolic changes similar to those seen in metabolic syn-
drome, which is defined as the presence of three of the 
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following: central obesity, hyperglycaemia, hypertension 
or elevated serum triglycerides and low high-density lipo-
protein (HDL) cholesterol [38]. However, the metabolic 
effects of lowered testosterone levels are more likely to 
promote CVD in the long term than during the first year 
of ADT, and the differing pattern of CV events associated 
with GnRH agonists and antagonists suggests that lowered 
testosterone might not be the sole cause of CVD in patients 
receiving ADT [40].
An alternative explanation for the association of CVD 
with GnRH agonists is the destabilisation of existing vas-
cular lesions: rupture of atherosclerotic plaques appears to 
be the cause of most acute CV events [48, 49]. In contrast 
to stable plaques, unstable plaques have a large lipid core, 
containing thrombogenic macrophages covered by a thin 
fibrous cap. Paradoxically, these vulnerable plaques often 
have a well-preserved lumen. T lymphocytes may destabi-
lise vulnerable fibrous caps in two ways. Firstly, releasing 
pro-inflammatory cytokines prevents synthesis of colla-
gen required to maintain the fibrous cap. Secondly, releas-
ing cytokine CD40L stimulates infiltrating macrophages 
to secrete collagenases that degrade the fibrous cap [48]. 
These T lymphocytes express GnRH receptors that are sen-
sitive to GnRH agonists and antagonists [50, 51]. GnRH 
agonist is likely to lead to increased proliferation and activ-
ity of T cells [52], with resulting fibrotic cap disruption and 
plaque instability. By contrast, a GnRH antagonist would 
not cause increased proliferation or activity, and plaque sta-
bility would be maintained.
CV risk stratification
CV risk can inform treatment decisions for ADT and guide 
CV risk reduction strategies, such as lifestyle modification 
(e.g. smoking cessation, diet and exercise), antihypertensive 
therapy, lipid-lowering therapy (e.g. statins) and antiplatelet 
therapy. GPs are generally well versed in this area, and the 
additional CV risk among some patients receiving GnRH 
agonists should be highlighted to GPs so they can provide 
appropriate management.
The new Joint British Societies (JBS3) risk calculator 
tool [53] is being promoted for use in conjunction with a 
healthcare provider, but may also be used by patients alone. 
The key message of the tool is that reducing risk factors 
by making lifestyle changes will provide long-term ben-
efits and extend the patient’s healthy life. Conversely, the 
JBS3 risk calculator may prevent a patient who otherwise 
has optimal risk factors being recommended a statin on the 
basis of age alone (Table 1; Fig. 2). 
Management of CV and other risk factors
Having assessed CV risk, clinicians should consider ADT 
options accordingly:
•	 In the low-CV-risk patient, clinicians should select the 
best therapy for the individual based on disease charac-
teristics
•	 In the presence of pre-existing or significant CV risk, 
consider the use of degarelix
Once an increased CV risk has been identified, patients 
should not only be offered the optimal ADT modality for 
their risk status, but should also be offered support in man-
aging their CV condition. Options include pharmacologi-
cal therapy to reduce CV risk (antihypertensives, statins, 
etc.) and professional support with lifestyle interventions, 
including diet, activity/exercise and smoking cessation 
advice [53]. ADT modality should be considered particu-
larly carefully in light of recent research demonstrating the 
Table 1  Key recommendations from the JBS3 risk calculator tool
CKD chronic kidney disease, FH familial hypercholesterolaemia, HDL high-density lipoprotein, LDL low-density lipoprotein
The risk calculator is not appropriate for diabetic patients aged over 40 years, those with CKD Stages 3–5 or those with FH
A non-fasting blood sample should be used for lipid profile estimation, measuring total cholesterol and HDL cholesterol
Non-HDL cholesterol should be used in preference to LDL cholesterol as the treatment goal for lipid-lowering therapy
Non-HDL cholesterol is based on non-fasting total cholesterol minus HDL cholesterol
Patients with existing CVD require intensive risk factor modification with diet, lifestyle and drug therapy, without the need for estimation of 
future risk
This also applies to those with diabetes older than 40 years and those with CKD Stages 3–5 or FH
Clear lifestyle guidance is provided on a healthy diet and physical activity, with support for an increase in exercise on referral and community-
based exercise initiatives
All healthcare professionals should be able to Ask and Assess adiposity and Advise (The 3 As) appropriate adult patients on evidence-based 
ways to lose weight
The lipid recommendations endorse the use of non-HDL cholesterol and all high-risk patients should receive professional lifestyle support to 
reduce total cholesterol, raise HDL cholesterol and lower triglycerides
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potential survival benefits associated with use of chemo-
therapy alongside ADT (for hormone-sensitive metastatic 
disease). One consequence of improved survival in this 
setting is longer-term exposure to ADT and potentially to 
increased CV risk [54, 55].
Given that PC patients tend to be aged 65 years or older 
and that agonist-based ADT is associated with osteope-
nia and increased fracture risk [3], it may be appropri-
ate to offer bone densitometry testing using dual energy 
X-ray absorptiometry (DEXA). Blood tests may also be 
appropriate to diagnose diabetes mellitus and metabolic 
syndrome.
Overall, attention should be paid to the patient’s QoL 
and personal treatment goals. As cancer treatments improve 
and patients are living for longer following diagnosis, there 
has been an increasing awareness of the need to provide 
the care and support required for them to lead healthy and 
active lives. The NICE prostate cancer guidelines CG175 
[8] state that all men receiving ADT should be prescribed 
a 12-week supervised exercise intervention consisting of 
aerobic and resistance exercise. Whereas this recommenda-
tion is based primarily on demonstration of improved QoL 
and reduction in fatigue [56], mechanistic evidence exists 
suggesting improvement in endothelial function from such 
an intervention, thus a possible impact on reducing CV 
risk [57].
Conclusions
PC remains the most frequently occurring male cancer in the 
UK. The majority of cases of PC respond, at least initially, 
to suppression of testosterone by the available options for 
ADT. Although GnRH agonists have become established the 
most common option, they have certain disadvantages, not 
least being the initial surge in testosterone, which may have 
serious clinical implications. The more recently available 
GnRH antagonists provide similar testosterone suppression, 
but have the major advantage of more rapid suppression of 
testosterone, brought about by blockage of the GnRH signal 
to the pituitary, with consequent rapid decreases in PSA, LH 
and FSH levels. The shortened PSA half-life, compared with 
agonists, may be of prognostic significance [9]. Antagonist-
based testosterone suppression is also more predictably sus-
tained in the longer term, with less breakthrough than seen 
with agonists, and may offer improved disease control, com-
pared with GnRH agonists [15].
Antagonists are also associated with a reduced risk of 
CV events in men with pre-existing CVD, compared with 
agonists. Mechanisms by which the different CVD risks 
of agonists and antagonists may occur are still being eluci-
dated, but it seems increasingly likely that GnRH agonists 
stimulate T cell-mediated pro-inflammatory responses, 
leading to destabilisation of atherosclerotic plaques.
Fig. 2  JBS3 algorithm for CV 
risk calculator
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Treatment decisions in PC should always be based on a 
number of considerations, including an individual patient’s 
disease characteristics, other comorbidities and his treat-
ment preferences. Given the demographics of the patient 
population, it is reasonable to assume that a degree of CVD 
may be present, although it may be sub-clinical. By carry-
ing out a simple series of tests, it is possible to assess an 
individual patient’s CVD risk. We are entering a time of 
more individualised care, with a greater tailoring of treat-
ment to each patient. Where we have choice, such as in the 
ADT phase of PC treatment, habit no longer has a place. 
All options should be considered, discussed and selected 
based on the benefits and risks associated with each. For 
patients with advanced PC, starving the tumour of testos-
terone is key, but the method by which this is achieved 
should also take into account the individual patient’s dis-
ease characteristics and other circumstances. In those men 
with underlying conditions, such as CVD or osteopenia, 
choice of ADT approach should be guided by the additional 
risk associated with those conditions.
Acknowledgments The authors thank Mark Loughlin (NexGen 
Healthcare Communications, UK) for medical writing services, which 
was funded by Ferring Pharmaceuticals Ltd (UK). Heather Payne’s 
work was supported by the UCLH/UCL Comprehensive Biomedical 
Research Centre.
Compliance with ethical standards 
Conflict of interest None.
Open Access This article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://crea-
tivecommons.org/licenses/by/4.0/), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
 1. WHO. GLOBOCAN 2012. http://globocan.iarc.fr/Default.aspx
 2. Huggins C (1942) Effect of orchiectomy and irradia-
tion on cancer of the prostate*. Ann Surg 115:1192–1200. 
doi:10.1097/00000658-194206000-00030
 3. Drudge-coates L (2009) GnRH blockers: a changing paradigm in 
the management of prostate cancer. Int J Urol Nurs 3:85–92
 4. Levine GN, D’Amico AV, Berger P, Clark PE, Eckel RH, Keating 
NL et al (2010) Androgen-deprivation therapy in prostate cancer 
and cardiovascular risk: a science advisory from the American 
Heart Association, American Cancer Society, and American 
Urological Association: endorsed by the American Society for 
Radiation Oncology. Circulation 121:833–840. doi:10.1161/
CIRCULATIONAHA.109.192695
 5. Mottet N, Bellmunt J, Briers E et al (2015) EAU guidelines on 
prostate cancer. http://uroweb.org/wp-content/uploads/09-Pros-
tate-Cancer_LR.pdf. Accessed 23 Feb 2016
 6. Perlmutter MA, Lepor H (2007) Androgen deprivation therapy 
in the treatment of advanced prostate cancer. Rev Urol 9(Suppl 
1):S3–S8
 7. Sharifi N, Gulley JL, Dahut WL (2005) Androgen deprivation 
therapy for prostate cancer. JAMA 294:238–244. doi:10.1001/
jama.294.2.238
 8. Nice (2014) Prostate cancer: diagnosis and treatment. Clinical 
guidelines 175. Natl Institute Heal Care Excell
 9. Van Poppel H, Klotz L (2012) Gonadotropin-releasing hormone: 
an update review of the antagonists versus agonists. Int J Urol 
19:594–601. doi:10.1111/j.1442-2042.2012.02997.x
 10. Bubley GJ (2001) Is the flare phenomenon clinically significant? 
Urology 58:5–9. doi:10.1016/S0090-4295(01)01235-3
 11. Tombal B (2005) Appropriate castration with luteinising hor-
mone releasing hormone (LHRH) agonists: what is the optimal 
level of testosterone? Eur Urol Suppl 4:14–19. doi:10.1016/j.
eursup.2005.04.004
 12. Tombal B, Berges R (2008) Optimal control of testosterone: a clin-
ical case-based approach of modern androgen-deprivation therapy. 
Eur Urol Suppl 7:15–21. doi:10.1016/j.eursup.2007.11.001
 13. Tombal B, Berges R (2005) How good do current LHRH ago-
nists control testosterone? Can this be improved with Eligard®? 
Eur Urol Suppl 4:30–36. doi:10.1016/j.eursup.2005.08.004
 14. Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI 
(2000) Reassessment of the definition of castrate levels of tes-
tosterone: implications for clinical decision making. Urology 
56:1021–1024. doi:10.1016/S0090-4295(00)00793-7
 15. Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson 
BE, Cantor P et al (2008) The efficacy and safety of degarelix: 
a 12-month, comparative, randomized, open-label, parallel-
group phase III study in patients with prostate cancer. BJU Int 
102:1531–1538. doi:10.1111/j.1464-410X.2008.08183.x
 16. Shore ND (2013) Experience with degarelix in the treat-
ment of prostate cancer. Ther Adv Urol 5:11–24. 
doi:10.1177/1756287212461048
 17. Crawford ED, Tombal B, Miller K, Boccon-Gibod L, Schröder 
F, Shore N et al (2011) A phase III extension trial with a 1-arm 
crossover from leuprolide to degarelix: comparison of gonado-
tropin-releasing hormone agonist and antagonist effect on pros-
tate cancer. J Urol 186:889–897. doi:10.1016/j.juro.2011.04.083
 18. Klotz L, Miller K, Crawford ED, Shore N, Tombal B, Karup C 
et al (2014) Disease control outcomes from analysis of pooled 
individual patient data from five comparative randomised clini-
cal trials of degarelix versus luteinising hormone-releasing hor-
mone agonists. Eur Urol. doi:10.1016/j.eururo.2013.12.063
 19. Radu A, Pichon C, Camparo P, Antoine M, Allory Y, Couve-
lard A et al (2010) Expression of follicle-stimulating hormone 
receptor in tumor blood vessels. N Engl J Med 363:1621–1630. 
doi:10.1056/NEJMoa1001283
 20. Blair HC, Robinson LJ, Sun L, Isales C, Davies TF, Zaidi 
M (2011) Skeletal receptors for steroid-family regulat-
ing glycoprotein hormones: a multilevel, integrated physi-
ological control system. Ann NY Acad Sci 1240:26–31. 
doi:10.1111/j.1749-6632.2011.06287.x
 21. Ilic D, Neuberger MM, Djulbegovic M, Dahm P (2013) 
Screening for prostate cancer. Cochrane Database Syst Rev 
1:CD004720. doi:10.1002/14651858.CD004720.pub3
 22. Tombal B, Miller K, Boccon-Gibod L, Schröder F, Shore N, 
Crawford ED et al (2010) Additional analysis of the second-
ary end point of biochemical recurrence rate in a phase 3 trial 
(CS21) comparing degarelix 80 mg versus leuprolide in prostate 
cancer patients segmented by baseline characteristics. Eur Urol 
57:836–842. doi:10.1016/j.eururo.2009.11.029
 23. Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner 
J, Crawford ED et al (2006) Absolute prostate-specific anti-
gen value after androgen deprivation is a strong independent 
 World J Urol
1 3
predictor of survival in new metastatic prostate cancer: data from 
Southwest Oncology Group trial 9346 (INT-0162). J Clin Oncol 
24:3984–3990. doi:10.1200/JCO.2006.06.4246
 24. Hussain MHA, Goldman B, Tangen C, Higano CS, Petrylak DP, 
Wilding G et al (2009) Prostate-specific antigen progression pre-
dicts overall survival in patients with metastatic prostate cancer: 
data from Southwest Oncology Group trials 9346 (intergroup 
study 0162) and 9916. J Clin Oncol 27:2450–2456. doi:10.1200/
JCO.2008.19.9810
 25. Lin G-W, Yao X-D, Zhang S-L, Dai B, Ma C-G, Zhang H-L 
et al (2009) Prostate-specific antigen half-life: a new predictor 
of progression-free survival and overall survival in Chinese pros-
tate cancer patients. Asian J Androl 11:443–450. doi:10.1038/
aja.2008.36
 26. Hanninen M, Venner P, North S (2009) A rapid psa half-life fol-
lowing docetaxel chemotherapy is associated with improved sur-
vival in hormone refractory prostate cancer. J Can Urol Assoc 
3:369–374
 27. Boccon-Gibod L, van der Meulen E, Persson B-E (2011) An update 
on the use of gonadotropin-releasing hormone antagonists in prostate 
cancer. Ther Adv Urol 3:127–140. doi:10.1177/1756287211414457
 28. Plekhanov A, Crawford ED, Olesen TK, van der Meulen E 
(2010) Switching from leuprolide to degarelix vs continuous 
degarelix treatment—effects on long-term prostate-specific anti-
gen control. J Urol 183:e262. doi:10.1016/j.juro.2010.02.1057
 29. Schwartz GG (2008) Prostate cancer, serum parathyroid hor-
mone, and the progression of skeletal metastases. Cancer Epi-
demiol Biomarkers Prev 17:478–483. doi:10.1158/1055-9965.
EPI-07-2747
 30. Robinson D, Sandblom G, Johansson R, Garmo H, Stattin P, 
Mommsen S et al (2008) Prediction of survival of metastatic 
prostate cancer based on early serial measurements of prostate 
specific antigen and alkaline phosphatase. J Urol 179:117–22; 
discussion 122–123. doi:10.1016/j.juro.2007.08.132
 31. Schröder FH, Tombal B, Miller K, Boccon-Gibod L, Shore ND, 
Crawford ED et al (2009) Changes in alkaline phosphatase levels 
in patients with prostate cancer receiving degarelix or leuprolide: 
results from a 12-month, comparative, phase III study. BJU Int 
106:182–187. doi:10.1111/j.1464-410X.2009.08981.x
 32. Turner B, Drudge-Coates L, Pati J (2011) “Nurse: my 
back hurts!”: Case study review of Degarelix in met-
astatic prostate cancer. Int J Urol Nurs 5:90–94. 
doi:10.1111/j.1749-771X.2011.01109.x
 33. Turner B, Goldstraw E, Pati J, Green J (2013) Degarelix relieves 
hydronephrosis in a patient with prostate cancer: case study. Int J 
Urol Nurs 7:166–169
 34. Chao HH, Uchio E, Zhang S, Hu S, Bednarski SR, Luo X et al 
(2012) Effects of androgen deprivation on brain function in pros-
tate cancer patients—a prospective observational cohort analysis. 
BMC Cancer 12:371. doi:10.1186/1471-2407-12-371
 35. Green HJ, Pakenham KI, Headley BC, Yaxley J, Nicol DL, Mac-
taggart PN et al (2002) Altered cognitive function in men treated 
for prostate cancer with luteinizing hormone-releasing hormone 
analogues and cyproterone acetate: a randomized controlled trial. 
BJU Int 90:427–432. doi:10.1046/j.1464-410X.2002.02917.x
 36. Nelson CJ, Lee JS, Gamboa MC, Roth AJ (2008) Cognitive 
effects of hormone therapy in men with prostate cancer: a review. 
Cancer 113:1097–1106. doi:10.1002/cncr.23658
 37. Wilson JM, Atkinson C, Hughes S (2013) Management of erec-
tile dysfunction in men treated with androgen deprivation ther-
apy. Trends Urol Men’s Health 4(3):13–18
 38. Kelly DM, Jones TH (2013) Testosterone: a metabolic hormone 
in health and disease. J Endocrinol 217:R25–R45. doi:10.1530/
JOE-12-0455
 39. Saylor PJ, Smith MR (2009) Metabolic complications of 
androgen deprivation therapy for prostate cancer. J Urol 
181:1998–2006; discussion 2007–2008. doi:10.1016/j.
juro.2009.01.047
 40. Albertsen PC, Klotz L, Tombal B, Grady J, Olesen TK, Nilsson 
J (2014) Cardiovascular morbidity associated with gonadotropin 
releasing hormone agonists and an antagonist. Eur Urol 65:565–
573. doi:10.1016/j.eururo.2013.10.032
 41. Keating NL, O’Malley AJ, Smith MR (2006) Diabetes and 
cardiovascular disease during androgen deprivation therapy 
for prostate cancer. J Clin Oncol 24:4448–4456. doi:10.1200/
JCO.2006.06.2497
 42. Nanda A, Chen M-H, Braccioforte MH, Moran BJ, D’Amico AV 
(2009) Hormonal therapy use for prostate cancer and mortality in 
men with coronary artery disease-induced congestive heart fail-
ure or myocardial infarction. JAMA 302:866–873. doi:10.1001/
jama.2009.1137
 43. Van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt 
O, Bill-Axelson A et al (2010) Absolute and relative risk of car-
diovascular disease in men with prostate cancer: results from the 
population-based PCBaSe Sweden. J Clin Oncol 28:3448–3456. 
doi:10.1200/JCO.2010.29.1567
 44. Ehdaie B, Atoria CL, Gupta A, Feifer A, Lowrance WT, Mor-
ris MJ et al (2012) Androgen deprivation and thromboembolic 
events in men with prostate cancer. Cancer 118:3397–3406. 
doi:10.1002/cncr.26623
 45. Satariano WA, Ragland KE, Van Den Eeden SK (1998) 
Cause of death in men diagnosed with prostate carci-
noma. Cancer 83:1180–1188. doi:10.1002/(SICI)1097-
0142(19980915)83:6<1180:AID-CNCR18>3.0.CO;2-1
 46. FDA. Fda note to correspondents 2010. www.fda.gov/NewsEv-
ents/Newsroom/PressAnnouncements/ucm230334.htm
 47. Scandanavian Simvastatin Survival Study Group (1994) Ran-
domised trial of cholesterol lowering in 4444 patients with 
coronary heart disease: the Scandinavian Simvastatin Sur-
vival Study (4S). Lancet 344:1383–1389. doi:10.1016/j.
atherosclerosissup.2004.08.027
 48. Libby P (2009) Molecular and cellular mechanisms of the 
thrombotic complications of atherosclerosis. J Lipid Res 
50(Suppl):S352–S357. doi:10.1194/jlr.R800099-JLR200
 49. Libby P (1995) Molecular bases of the acute coronary syn-
dromes. Circulation 91:2844–2850
 50. Chen H, Jeung E, Stephenson M, Leung PCK (1999) Ribonu-
cleic acids that are regulated by GnRH in vitro. Endocrinol 
Metab 84:743–750
 51. Tanriverdi F, Gonzalez-Martinez D, Hu Y, Kelestimur F, Bou-
loux PMG (2005) GnRH-I and GnRH-II have differential mod-
ulatory effects on human peripheral blood mononuclear cell 
proliferation and interleukin-2 receptor gamma-chain mRNA 
expression in healthy males. Clin Exp Immunol 142:103–110. 
doi:10.1111/j.1365-2249.2005.02904.x
 52. Jacobson JD, Nisula BC, Steinberg AD (1994) Modulation of 
the expression of murine lupus by gonadotropin-releasing hor-
mone analogs. Endocrinology 134:2516–2523. doi:10.1210/
en.134.6.2516
 53. JBS3 Board (2014) Joint British Societies’ consensus recom-
mendations for the prevention of cardiovascular disease (JBS3). 
Heart 100(Suppl):ii1–ii67. doi:10.1136/heartjnl-2014-305693
 54. Sweeney CJ, Chen Y-H, Carducci M, Liu G, Jarrard DF, Eisen-
berger M et al (2015) Chemohormonal Therapy in Metastatic 
Hormone-Sensitive Prostate Cancer. N Engl J Med 373:737–746. 
doi:10.1056/NEJMoa1503747
 55. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, 
Spears MR et al (2015) Addition of docetaxel, zoledronic acid, 
or both to first-line long-term hormone therapy in prostate cancer 
(STAMPEDE): survival results from an adaptive, multiarm, mul-
tistage, platform randomised controlled trial. Lancet (London, 
England) 2015. doi:10.1016/S0140-6736(15)01037-5
World J Urol 
1 3
 56. Bourke L, Hooper R, Steed LA, Joshi M, Gilbert S, Saxton JM, 
Catto JWF, Rosario DJ (2013) Lifestyle changes for improv-
ing disease-specific quality of life in sedentary men on long-
term androgen-deprivation therapy for advanced prostate can-
cer: a randomised controlled trial. Eur Urol 65(5):865–872. 
doi:10.1016/j.eururo.2013.09.040
 57. Gilbert S et al (2016) Effects of a lifestyle intervention on 
endothelial function in men on long-term androgen depriva-
tion therapy for prostate cancer. Br J Cancer 114(4):401–408. 
doi:10.1038/bjc.2015.479
